May 2, 2017 06:59 AM EDT
Financing
Startups

Five months, $98.5M and a PhII drug from No­var­tis lat­er, Ma­gen­ta Ther­a­peu­tics is floor­ing it

John Carroll

Editor & Founder

Last No­vem­ber, Ma­gen­ta Ther­a­peu­tics end­ed a year of self-im­posed start­up si­lence with a hefty $48.5 mil­lion Se­ries A and a bur­geon­ing team of in­ves­ti­ga­tors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

A service from the Financial Times